Archive by Author
PM 2 site 207

Endocannabinoid Signalling in Atherosclerosis and Related Metabolic Complications.

Thromb Haemost. 2019 Feb 15. doi: 10.1055/s-0039-1678738. [Epub ahead of print] Guillamat-Prats R1, Rami M1, Herzig S2,3,4, Steffens S1,5. Author information Abstract Endocannabinoids are a group of arachidonic acid-derived lipid mediators binding to cannabinoid receptors CB1 and CB2. An overactivity of the endocannabinoid system plays a pathophysiological role in the development of visceral obesity and […]

PM 2 site 207

Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.

Expert Rev Clin Pharmacol. 2019 Feb 15. doi: 10.1080/17512433.2019.1582330. [Epub ahead of print] Halbmeijer N1, Groeneweg M1, de Ridder L2. Author information Abstract The onset of inflammatory bowel disease (IBD) in children is rising. Current treatment options are based on immunomodulatory therapy. Alternative treatment options are upcoming since they appear to be effective in individual […]

PM 2 site 207

Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of cannabis galenical preparation (Bedrocan).

Int J Pharm Pract. 2019 Feb 15. doi: 10.1111/ijpp.12514. [Epub ahead of print] Palmieri B1,2, Laurino C1,2, Vadalà M1,2. Author information Abstract OBJECTIVES: Our main aim was to investigate the short-term therapeutic effects, safety/tolerability and potential side effects of the cannabis galenical preparation (Bedrocan) in patients with a range of chronic conditions unresponsive to other […]


Pharmacists should counsel users of medical cannabis, but should they be dispensing it?

Journal ListCan Pharm J (Ott)v.152(1); Jan-Feb 2019PMC6346339 Can Pharm J (Ott). 2019 Jan-Feb; 152(1): 10–13. Published online 2018 Dec 12. doi: 10.1177/1715163518814273 PMCID: PMC6346339 PMID: 30719190 Pharmacists should counsel users of medical cannabis, but should they be dispensing it? Paul Grootendorst, PhD and Rajivi Ranjithan, BSc, PharmD candidate Author information Copyright and License information Disclaimer Canada […]

PM 2 site 207

Cardiovascular effects of cannabis (marijuana): A timely update.

Phytother Res. 2019 Feb 14. doi: 10.1002/ptr.6315. [Epub ahead of print] Sánchez Artiles AE1, Awan A1, Karl M1, Santini A2. Author information Abstract Cannabis (medical marijuana) is generally considered a low toxicity drug. The plant belongs to the family Cannabaceae (Urticales). Two main species may be recognized: Cannabis sativa and Cannabis indica. Plants of this […]

PM 2 site 207

New Insights in Cannabinoid Receptor Structure and Signaling.

Curr Mol Pharmacol. 2019 Feb 14. doi: 10.2174/1874467212666190215112036. [Epub ahead of print] Ye L1, Cao Z1, Wang W1, Zhou N1. Author information Abstract BACKGROUND: Cannabinoid has long been used for medicinal purposes. Cannabinoid signaling has been considered the therapeutic targets for treating pain, addiction, obesity, inflammation, and other diseases. Recent studies have suggested that in […]

PM 2 site 207

Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases.

J Palliat Med. 2019 Feb 13. doi: 10.1089/jpm.2018.0551. [Epub ahead of print] Carr C1, Vertelney H2, Fronk J3, Trieu S4. Author information Abstract BACKGROUND: Night sweats significantly impact the quality of life for cancer patients and are often resistant to treatment. Cannabinoids have been shown to modulate cytokine activity and produce hypothermia in animal models, […]

PM 2 site 207

Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial.

BMC Psychiatry. 2019 Feb 13;19(1):69. doi: 10.1186/s12888-019-2022-x. van der Flier FE1,2,3,4, Kwee CMB2, Cath DC2,5,6, Batelaan NM3, Groenink L7, Duits P2, van der Veen DC4, van Balkom AJLM3, Baas JMP8. Author information Abstract BACKGROUND: Phobic anxiety disorders are among the most prevalent psychiatric disorders and are burdensome in terms of loss of quality of life […]

PM 2 site 207

On the influence of cannabinoids on cell morphology and motility of glioblastoma cells.

PLoS One. 2019 Feb 12;14(2):e0212037. doi: 10.1371/journal.pone.0212037. eCollection 2019. Hohmann T1, Feese K1, Ghadban C1, Dehghani F1, Grabiec U1. Author information Abstract The mechanisms behind the anti-tumoral effects of cannabinoids by impacting the migratory activity of tumor cells are only partially understood. Previous studies demonstrated that cannabinoids altered the organization of the actin cytoskeleton in […]